VivoSphere

What VivoSphere does

VivoSphere is a privately held biotechnology company headquartered at the Auburn University New Venture Accelerator in Auburn, Alabama, with a regional subsidiary (VivoSphere UK) launched in 2024. The company develops 3D tissue-engineered models for in vitro drug discovery and toxicity testing, built around a proprietary high-density cell encapsulation method and a microfluidic fabrication platform that the co-founders co-invented. Its product surface spans standardized 3D cell culture models, pre-validated assay-ready tissues, customizable hydrogel-based tissue microenvironments, and custom model development services, with explicit compatibility for high-throughput screening and lab automation workflows.

The company sells to pharmaceutical companies, biotechnology firms, academic research institutions, contract research organizations, and — at the exploratory end — healthcare providers pursuing precision-medicine applications. Pricing is not publicly disclosed; the company runs a direct, quote-based enterprise sales motion supplemented by academic-industry partnerships (notably with Auburn University), industry conferences (BIO, SLAS, AACR, BioAlabama, MPS World Summit), and accelerator programs (Gener8tor, Hatch/Bessel). VivoSphere has funded operations exclusively through non-dilutive grants — including NSF I-Corps, NSF Phase I STTR, a $350K NIH award, Alabama Launchpad, and Innovate Alabama — and remains in a pre-commercial or very early-commercial stage with a 1–10 person team led by co-founders Dr. Elizabeth Lipke (CSO) and Dr. Yuan Tian (CTO).

Name

VivoSphere

Legal name

VivoSphere, LLC

Website

https://vivospheres.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

VivoSphere is a privately held biotech company developing 3D tissue-engineered in vitro models — built on proprietary high-density cell encapsulation and microfluidic fabrication — for drug discovery and toxicity testing by pharmaceutical, biotechnology, academic, and CRO customers.

Ownership category

akta.pro rank

Product category

3D Tissue-Engineered Cell Culture Models

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ)

Keywords

• 3D cell culture models
• Tissue-engineered models
• Drug discovery tools
• In vitro toxicity testing
• High-throughput screening

Headquarters

HQ city

Auburn

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. 3D Cell Culture Models and Assay-Ready Tissues: Sale of standardized 3D tissue-engineered models and pre-validated assay-ready tissues for drug discovery and toxicity testing. These are sold as products with direct sales engagement to pharmaceutical and biotech companies.
2. Custom Model Development Services: Tailored 3D tissue model development services for specific research needs in oncology, toxicology, and regenerative medicine applications.
3. Research Collaborations & Partnerships: Collaborative research arrangements with universities, biotech firms, and pharmaceutical companies for joint development of advanced in vitro models and tissue engineering solutions.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Core offering

VivoSphere develops and manufactures 3D tissue-engineered models and assay-ready tissues for pharmaceutical, biotechnology, and academic research customers conducting in vitro drug discovery and toxicity testing. The company combines proprietary high-density cell encapsulation with a microfluidic fabrication platform to produce physiologically relevant tissue microenvironments that are more predictive than traditional 2D cultures. Revenue is generated through direct product sales of standardized models, custom model development services, and collaborative research engagements.

Product overview

VivoSphere is a biotech company offering a portfolio of 3D tissue-engineered models for in vitro drug discovery and toxicity testing. The core offerings consist of 3D Cell Culture Models, Assay-Ready Tissues, and Customized Solutions, supported by Tissue Engineering & High-Throughput Screening Services and Custom Model Development. These products provide physiologically relevant alternatives to traditional 2D cultures and animal testing, enabling researchers to generate more human-like tissue responses for improved preclinical data translatability.

Differentiator

Problem solved

Functional benefit

Products and services

• 3D Cell Culture Models Standardized 3D tissue-engineered cell culture models that replicate natural tissue microenvironments, enhancing cell-to-cell interactions and improving drug discovery accuracy and toxicity testing predictability for pharmaceutical, biotech, and academic researchers.
• Assay-Ready 3D Tissues Pre-validated, ready-to-use 3D tissue products designed for high-throughput drug screening and toxicity testing, providing physiologically relevant data with reliability, scalability, and compatibility with laboratory automation systems.
• Custom Model Development Services Custom 3D tissue model development services tailored to specific research needs using advanced bioengineering techniques, including tailored microenvironments for disease modeling, oncology research, regenerative medicine, and tissue engineering and high-throughput screening programs.

Quantifiable outcome

• Enhanced drug responses observed in 3D tumor models compared to traditional 2D cultures
• +2 more outcomes

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Hatch Fairhope / BesselcoreStrategic or Co-development Partner · 7 May 2026VivoSphere participated in the Hatch Powered by Bessel second annual biotech and medtech accelerator program, a 12-week program delivering 240+ hours of mentorship. The program supports companies across two years totaling 432+ hours of direct mentorship and positions the Gulf Coast as a emerging biotech hub.
• Gener8torcoreStrategic or Co-development Partner · 1 January 2026VivoSphere is participating in the Gener8tor gBETA accelerator program Spring 2026 focused on health technology innovation. Gener8tor is a nationally ranked accelerator that provides mentorship, capital, and network access to startups.
• Society for Laboratory Automation and Screening (SLAS)minorStrategic or Co-development Partner · 1 January 2024VivoSphere was nominated for the 2024 SLAS Ignite Award and selected as SLAS2024 Innovation AveNEW company for meeting at the SLAS2024 International Conference & Exhibition in Boston.
• Auburn University / AU New Venture AcceleratorcoreStrategic or Co-development PartnerVivoSphere is based at AU New Venture Accelerator in Auburn, AL. The company originated from Auburn University Chemical Engineering faculty research. Dr. Elizabeth Lipke and Dr. Yuan Tian are Auburn University faculty co-founders. Featured by Auburn University College of Engineering news and Auburn University New Venture Accelerator.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• InSphero: InSphero commercializes 3D microtissue models (liver, pancreatic islet, tumor) for drug discovery and toxicity testing — the most direct comparator to VivoSphere's 3D cell culture / assay-ready tissue business.
• Mimetas: Mimetas sells the OrganoPlate platform for organ-on-chip and 3D tissue models used in pharma preclinical screening; comparable in technology (microfluidic 3D cultures) and customer base (big-pharma toxicology/screening groups).
• CN Bio Innovations: CN Bio offers single- and multi-organ microfluidic chips (PhysioMimix) for drug discovery and toxicity testing, directly overlapping with VivoSphere's microfluidic encapsulation-based preclinical platform.
• Emulate: Emulate's organ-on-chip platform replicates human tissue responses for pharma R&D; a scaled direct competitor pursuing the same pharma/biotech preclinical screening accounts.
• TissUse: TissUse develops multi-organ-chip systems for ADME, toxicity, and disease modeling — a direct peer in microfluidic 3D tissue engineering for pharma preclinical applications.
• SynVivo: SynVivo provides microfluidic organ-on-chip and tumor-on-chip models for drug delivery and toxicity studies; comparable in microfluidic tissue modeling for preclinical research.

Broad incumbents

• Organovo: Organovo is a publicly listed 3D bioprinting company developing human tissue constructs for therapeutic and research use — a broader incumbent in the 3D tissue-engineering category encompassing VivoSphere's niche.

Emerging players

• Hurel Corporation: Hurel builds in vitro microfluidic tissue models for ADME-Tox testing, focused on liver and other organ models; an emerging player with overlapping technology and customer segments.
• DefiniGEN: DefiniGEN provides iPSC-derived human cell models (hepatocytes, pancreatic) for drug discovery and metabolic disease research — adjacent in the in vitro human-cell-model space.

Others

• CytoSMART: CytoSMART provides live-cell imaging and automated cell culture monitoring hardware — an adjacent enabling technology supplier to 3D tissue / organ-on-chip workflows rather than a direct competitor.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/vivosphere/posts/?feedView=all

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about VivoSphere